Kolck, Johannes http://orcid.org/0000-0001-9843-2247
Rako, Zvonimir A.
Beetz, Nick L.
Auer, Timo A.
Segger, Laura K.
Pille, Christian
Penzkofer, Tobias
Fehrenbach, Uli
Geisel, Dominik
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 5 April 2023
Accepted: 3 July 2023
First Online: 8 July 2023
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board (Internal registration number: EA4/152/20). Informed patient consent was waived by the IRB.
: Not applicable.
: Uli Fehrenbach reports research agreements with Bayer Healthcare and fees for lectures (Bayer Healthcare, Guerbet, GE, Siemens, Ipsen) as well as for attending meetings (Bayer Healthcare, Asahi Intecc, Ipsen).Tobias Penzkofer was supported by Berlin Institute of Health (Clinician Scientist Grant, Platform Grant), Ministry of Education and Research (BMBF, 01KX2021, 68GX21001A), German Research Foundation (DFG, SFB 1340/2), Horizon 2020 (952172) and reports research agreements (no personal payments, outside of submitted work) with AGO, Aprea AB, ARCAGY-GINECO, Astellas Pharma Global Inc. (APGD), Astra Zeneca, Clovis Oncology, Inc., Dohme Corp, Holaira, Incyte Corporation, Karyopharm, Lion Biotechnologies, Inc., MedImmune, Merck Sharp, Millennium Pharmaceuticals, Inc., Morphotec Inc., NovoCure Ltd., PharmaMar S.A. and PharmaMar USA, Inc., Roche, Siemens Healthineers, and TESARO Inc., and fees for a book translation (Elsevier).All other authors declare that they have no competing interests.